ASTH (Astrana Health) Current Deferred Revenue: $0 Mil (As of Mar. 2026)


ASTH Astrana Health Inc ASTH
87 GF Score
Price $49.17
GF Value $82.67
Valuation Significantly Undervalued
! 8 Warning Signs
View Full Analysis

What is Astrana Health Current Deferred Revenue?

Astrana Health ASTH -1.26% 87 Current Deferred Revenue is $0 Mil as of Mar. 2026. GuruFocus rates ASTH with a GF Score™ of 87/100 and a GF Value™ of $82.67 (Significantly Undervalued). The stock has 8 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Astrana Health's current deferred revenue for the quarter that ended in Mar. 2026 was $0 Mil.

Astrana Health Current Deferred Revenue Related Terms

Astrana Health Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Astrana Health's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astrana Health Current Deferred Revenue Chart

Astrana Health Annual Data
Trend Mar16 Mar17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.80 0.53 0.74 1.61 2.66

Astrana Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.00 0.00 2.66 0.00
ASTH
87GF Score
Astrana Health Inc ASTH
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0 Mil mean?
Astrana Health (ASTH) has a Current Deferred Revenue of $0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Astrana Health and its competitors.
Is Astrana Health's Current Deferred Revenue too high?
Astrana Health's current Current Deferred Revenue is $0 Mil. Overall, Astrana Health has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astrana Health's Current Deferred Revenue compare to SGRY and SEM?
Astrana Health's Current Deferred Revenue of $0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Healthcare Providers & Services company?
A good Current Deferred Revenue depends on the Healthcare Providers & Services industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Astrana Health and its competitors. Astrana Health's current Current Deferred Revenue is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astrana Health stock overvalued right now?
Based on GuruFocus' analysis, Astrana Health (ASTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $82.67, compared to a current price of $49.17 — trading 40.5% below its estimated fair value. The current Current Deferred Revenue is $0 Mil. Astrana Health's overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Astrana Health (ASTH), the current Current Deferred Revenue is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astrana Health (ASTH) Overvalued in 2026?

Based on GuruFocus' analysis, Astrana Health stock appears to be undervalued. The current stock price of $49.17 is trading 40.5% below its estimated GF Value™ of $82.67. GuruFocus considers Astrana Health to be Significantly Undervalued.

Key valuation signals for ASTH:

  • Current Deferred Revenue: $0 Mil
  • GF Value™: $82.67 vs. price of $49.17 (40.5% below fair value)
  • GF Score™: 87/100 with 8 warning signs

No single metric tells the full story. See the ASTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astrana Health Business Description

Other Exchanges 3AM:Germany
Address 1668 South Garfield Avenue, 2nd Floor, Alhambra, CA, USA, 91801
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
87GF Score

Get the complete analysis for ASTH

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$49.17
Price
$82.67
GF Value